Merck & Co at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Merck & Co at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Merck & Co Rahway, New Jersey	1 Scientist · 1 other presenter
merck.com\|LinkedIn Public company~75,000 people Merck sells prescription medicines, biologic therapies, vaccines, and animal-health products to human-health and animal-health customers. Reported positive Phase 3 results for its personalized cancer vaccine with Moderna combined with Keytruda, advancing a genomics-driven oncology approach. › Reported positive Phase 3 results for its personalized cancer vaccine with Moderna combined with Keytruda, advancing a genomics-driven oncology approach. 2026-08 · source Won FDA approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor, adding a new cardiovascular drug to its portfolio. 2026-07 · source Completed its acquisition of Terns Pharmaceuticals, adding the drug candidate TERN-701 to its pipeline. 2026-05 · source Source: company newsroom Q2 2026 sales $16.6B, up 5% YoY › FY2026 sales guidance is $66.3-67.3 billion, indicating a large, stable R&D budget. · 2026-08-04 “Total Worldwide Sales Were $16.6 Billion (5% Growth; 4% Growth ex-FX) / sales to be between $66.3 billion and $67.3 billion” Source: results release Currently hiring: 377 open roles › Source: careers page	Poster Thu Oct 22 4:15 pm Part of Omics Technologies Poster Thursday Session MGtree: a fast and flexible alignment-based metagenomics pipeline Exhibit & Poster Hall · Board 8165T Infectious diseaseGenomicsDiagnosticsComputational tools Session Fri Oct 23 2:45 pm Speed Mentoring Gene-ius Lounge, Exhibit & Poster Hall

Organization

ASHG 2026 Attendance

Merck & Co

Rahway, New Jersey

1 Scientist · 1 other presenter

merck.com|LinkedIn

Public company~75,000 people

Merck sells prescription medicines, biologic therapies, vaccines, and animal-health products to human-health and animal-health customers.

Reported positive Phase 3 results for its personalized cancer vaccine with Moderna combined with Keytruda, advancing a genomics-driven oncology approach.

›

Reported positive Phase 3 results for its personalized cancer vaccine with Moderna combined with Keytruda, advancing a genomics-driven oncology approach.

2026-08 · source

Won FDA approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor, adding a new cardiovascular drug to its portfolio.

2026-07 · source

Completed its acquisition of Terns Pharmaceuticals, adding the drug candidate TERN-701 to its pipeline.

2026-05 · source

Source: company newsroom

Q2 2026 sales $16.6B, up 5% YoY

›

FY2026 sales guidance is $66.3-67.3 billion, indicating a large, stable R&D budget. · 2026-08-04

“Total Worldwide Sales Were $16.6 Billion (5% Growth; 4% Growth ex-FX) / sales to be between $66.3 billion and $67.3 billion”

Source: results release

Currently hiring: 377 open roles

›

Source: careers page

Poster

Thu Oct 22
4:15 pm

Part of Omics Technologies Poster Thursday Session

MGtree: a fast and flexible alignment-based metagenomics pipeline

Exhibit & Poster Hall · Board 8165T

Infectious diseaseGenomicsDiagnosticsComputational tools

Session

Fri Oct 23
2:45 pm

Speed Mentoring

Gene-ius Lounge, Exhibit & Poster Hall

Instantly find 20 buyers from Merck & Co

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction